Beijing Tong Ren Tang Chinese Medicine Co Statistics
Beijing Tong Ren Tang Chinese Medicine Co (TQR) Stock Statistics & Valuation Metrics
Total Valuation
Beijing Tong Ren Tang Chinese Medicine Co has a market cap or net worth of EUR 533.06M. The enterprise value is EUR 3.52B.
- Market Cap
- EUR 533.06M
- Enterprise Value
- EUR 3.52B
Share Statistics
Beijing Tong Ren Tang Chinese Medicine Co has 837,100,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 837,100,000
- Owned by Insiders
- ―
- Owned by Institutions
- 3.56%
Financial Efficiency
Beijing Tong Ren Tang Chinese Medicine Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 8.66%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 8.66%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 1.98M
- Profits Per Employee
- 520.60K
- Employee Count
- 763
- Asset Turnover
- 0.32
- Inventory Turnover
- 0.44
Valuation Ratios
The current PE Ratio of Beijing Tong Ren Tang Chinese Medicine Co is 9.94. Beijing Tong Ren Tang Chinese Medicine Co’s PEG ratio is -0.88.
- PE Ratio
- 9.94
- PS Ratio
- 2.78
- PB Ratio
- 1.13
- Price to FCF
- 4.95
- Price to Operating Cash Flow
- 4.74
- PEG Ratio
- -0.88
Income Statement
In the last 12 months, Beijing Tong Ren Tang Chinese Medicine Co had revenue of 1.51B and earned 397.22M in profits. Earnings per share was 0.47.
- Revenue
- 1.51B
- Gross Profit
- 925.58M
- Operating Income
- 472.24M
- Pretax Income
- 504.69M
- Net Income
- 397.22M
- EBITDA
- 574.36M
- Earnings Per Share (EPS)
- 0.47
Cash Flow
In the last 12 months, operating cash flow was 969.98M and capital expenditures -41.11M, giving a free cash flow of 928.86M billion.
- Operating Cash Flow
- 969.98M
- Free Cash Flow
- 928.86M
- Free Cash Flow per Share
- 1.11
Dividends & Yields
Beijing Tong Ren Tang Chinese Medicine Co pays an annual dividend of ―, resulting in a dividend yield of 9.09%
- Dividend Per Share
- ―
- Dividend Yield
- 9.09%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 20.21%
- Earnings Yield
- 10.00%
Stock Price Statistics
- Beta
- 0.04
- 52-Week Price Change
- -38.38%
- 50-Day Moving Average
- 0.61
- 200-Day Moving Average
- 0.71
- Relative Strength Index (RSI)
- 46.44
- Average Volume (3m)
- 600
Important Dates
Beijing Tong Ren Tang Chinese Medicine Co upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Beijing Tong Ren Tang Chinese Medicine Co as a current ratio of 19.65, with Debt / Equity ratio of 3.02%
- Current Ratio
- 19.65
- Quick Ratio
- 13.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -3.66
- Interest Coverage Ratio
- 83.43
Taxes
In the past 12 months, Beijing Tong Ren Tang Chinese Medicine Co has paid 87.83M in taxes.
- Income Tax
- 87.83M
- Effective Tax Rate
- 0.17
Enterprise Valuation
Beijing Tong Ren Tang Chinese Medicine Co EV to EBITDA ratio is 3.75, with an EV/FCF ratio of 2.76.
- EV to Sales
- 1.55
- EV to EBITDA
- 3.75
- EV to Free Cash Flow
- 2.76
- EV to Operating Cash Flow
- 2.64
Balance Sheet
Beijing Tong Ren Tang Chinese Medicine Co has EUR 2.21B in cash and marketable securities with EUR 125.80M in debt, giving a net cash position of EUR 2.08B billion.
- Cash & Marketable Securities
- EUR 2.21B
- Total Debt
- EUR 125.80M
- Net Cash
- EUR 2.08B
- Net Cash Per Share
- EUR 2.49
- Tangible Book Value Per Share
- EUR 4.99
Margins
Gross margin is 62.83%, with operating margin of 32.25%, and net profit margin of 27.78%.
- Gross Margin
- 62.83%
- Operating Margin
- 32.25%
- Pretax Margin
- 34.16%
- Net Profit Margin
- 27.78%
- EBITDA Margin
- 41.36%
- EBIT Margin
- 32.47%
Analyst Forecast
The average price target for Beijing Tong Ren Tang Chinese Medicine Co is EUR 1.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 1.20
- Price Target Upside
- 96.49% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -26.39%
- EPS Growth Forecast
- -34.94%

